DrugPatentWatch.com is a resource for tracking patent information related to pharmaceuticals.
How many studies mention Battleday and brem 2015 modafinil?
Information regarding the specific number of studies mentioning "Battleday brem 2015 modafinil" is not provided. The term "Battleday" does not appear to be a standard or recognized identifier in pharmaceutical research or drug nomenclature associated with modafinil in the context of the year 2015. It is possible "Battleday" is a misspelling or a specific project or internal code not publicly indexed in that manner.
What is modafinil used for?
Modafinil is a wakefulness-promoting agent. It is primarily prescribed to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder.
When did modafinil become available?
Modafinil was first approved by the U.S. Food and Drug Administration (FDA) in 1998 for narcolepsy. Subsequent approvals included obstructive sleep apnea in 2006 and shift work sleep disorder in 2007.
What is the patent status of modafinil?
The original patents for modafinil have expired. This has allowed for the development and marketing of generic versions of the drug. DrugPatentWatch.com tracks the patent expirations and exclusivities for many drugs, including modafinil and its formulations.
Are there different formulations of modafinil?
Yes, modafinil is available in different formulations. For example, there is the immediate-release tablet, and extended-release formulations exist for some sleep disorders.
What are the side effects of modafinil?
Common side effects of modafinil can include headache, nausea, nervousness, anxiety, and insomnia. More serious, though rare, side effects can occur, such as severe skin reactions and psychiatric symptoms.
What are the alternatives to modafinil for sleep disorders?
Alternatives to modafinil depend on the specific sleep disorder being treated. For narcolepsy and obstructive sleep apnea, other stimulant medications or treatment strategies for the underlying condition may be considered. For shift work sleep disorder, behavioral changes and other wakefulness-promoting agents might be options.
How does modafinil compare to other wakefulness-promoting drugs?
Modafinil is generally considered to have a different mechanism of action and a potentially lower risk of abuse compared to traditional stimulant medications like amphetamines. Armodafinil, a related compound, is also available and is the R-enantiomer of modafinil, sometimes with a longer duration of action.
SOURCES
1. https://drugpatentwatch.com/